WaveMan
WaveMan · Company
NRXP · Nrx Pharmaceuticals, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

NRXP NRX Pharmaceuticals (NRXP) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001719406
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
35
13F, latest reported quarter

NRX Pharmaceuticals insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for NRX Pharmaceuticals, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Javitt Jonathan C
Chairman and Chief Scientist
BUY
2024-12-18 SECtraded 2024-12-17
40,000
$46.8K
+67.8%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (4 buys, 1 sale), the last on Aug 23, 2023.
  • +3.5% median (+6.7% mean) 90-day return after 3 previous buys.
  • The trade is 47.3% of the 84,634 shares held after it.
  • No other insider bought within 30 days.
  • 35 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chairman and Chief Scientist Javitt Jonathan C bought about $46.8K of NRXP on Dec 17, 2024, the largest insider purchase at the company since 2023; 35 funds added in the latest 13F quarter.
Gorovitz Aaron
Director
BUY
2023-09-11 SECtraded 2023-08-30
35,000
$11.2K
-2.3%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 33.3% of the 105,000 shares held after it.
  • 2 other insiders bought within 30 days.
  • 35 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Gorovitz Aaron bought about $11.2K of NRXP on Aug 30, 2023; 2 other insiders bought within 30 days and 35 funds added in the latest 13F quarter.
Hurvitz Chaim
Director
BUY
2023-09-11 SECtraded 2023-08-30
70,000
$20.3K
-2.3%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Nov 18, 2022.
  • -5.3% median (-4.6% mean) 90-day return after 3 previous buys.
  • The trade is 12.3% of the 570,000 shares held after it.
  • 2 other insiders bought within 30 days.
  • 35 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Hurvitz Chaim bought about $20.3K of NRXP on Aug 30, 2023; 2 other insiders bought within 30 days and 35 funds added in the latest 13F quarter.
Javitt Jonathan C
Chief Scientist
BUY
2023-08-24 SECtraded 2023-08-23
100,000
$33.0K
-20.3%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (3 buys, 1 sale), the last on Aug 22, 2023.
  • +8.3% median (+8.3% mean) 90-day return after 2 previous buys.
  • The trade is 22.4% of the 446,332 shares held after it.
  • 2 other insiders bought within 30 days.
  • 35 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Scientist Javitt Jonathan C bought about $33.0K of NRXP on Aug 23, 2023; 2 other insiders bought within 30 days and 35 funds added in the latest 13F quarter.
Javitt Jonathan C
Chief Scientist
BUY
2023-08-23 SECtraded 2023-08-22
200,000
$64.0K
-25.0%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (2 buys, 1 sale), the last on Dec 7, 2022.
  • The trade is 57.7% of the 346,332 shares held after it.
  • 2 other insiders bought within 30 days.
  • 35 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Scientist Javitt Jonathan C bought about $64.0K of NRXP on Aug 22, 2023; 2 other insiders bought within 30 days and 35 funds added in the latest 13F quarter.
30 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 25 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
35 funds bought in last quarter
below 60% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
-2336.5% net margin
below 93% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
26.6% of the float short (float per yahoo 2026-10-27) · 16.8 days to cover · settled 2026-10-15
more than 97% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch NRXP

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-20.3%12M
-48%-17%+14%+44%2025-102025-122026-022026-042026-062026-082026-10
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns NRXP: institutional holders (13F)

13F holdings, latest reported quarter
B Group, Inc.
4,091,767 sh
$16.7M
VANGUARD CAPITAL MANAGEMENT LLC
1,618,159 sh
$6.6M
AMERIPRISE FINANCIAL INC
928,728 sh
$3.8M
Balyasny Asset Management L.P.
893,864 sh
$3.7M
CITADEL ADVISORS LLC
680,043 sh
$2.8M

Congress trades in NRXP

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

NRXP planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

NRXP mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
AdvisorShares Psychedelics ETF
$2.7M position · as of 2026-06-30
6.1%
iShares Micro-Cap ETF
$429.3K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$29.1K position · as of 2026-06-30
0.0%
Victory Extended Market Index Fund
$13.5K position · as of 2026-07-31
0.0%
Fidelity Extended Market Index Fund
$580.3K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$1.2M position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 35 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

NRXP financials

Net margin
-2336.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$3.6M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-649.7%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$19.8M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Cash flow to debt
-2.16x
TTM operating cash flow over long-term 2024-06-30 (24 months older than the period end) plus current 2023-12-31 (30 months older than the period end)
Return on equity
n/a
average equity is zero or negative
Return on assets
-120.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
n/a
capital employed is zero or negative
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Enterprise value
$92.9M
market value at close 2026-10-26 on 2026-08-14 shares, plus long-term 2024-06-30 (24 months older than the period end) plus current 2023-12-31 (30 months older than the period end), minus cash 2026-06-30
FCF yield
-17.9%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$1.4M$0$0n/a
Operating income-$16.2M-$18.5M-$27.8M-$44.3M
Net income-$28.6M-$25.1M-$30.1M-$39.8M
EPS (diluted)n/an/an/a-0.60
Operating cash flow-$14.1M-$10.6M-$21.7M-$39.8M
Cash$7.8M$1.4M$4.6M$20.1M
Long-term debtn/an/a$9.2M$2.8M
SEC XBRL, fiscal years, as known on 2026-10-28

NRXP Stock Sonar score 3/7 axes

Find similar shapesCompare

NRXP ranks highest on institutional and government (47th percentile) and risk and compliance (47th), and lowest on financial health (43rd), among Pharma & Biotech peers.

Financial health
43
Inputs
  • Debt to equityequity is zero or negative, the ratio has no meaning
  • Cash flow to debt-2.16x · 43 pct, sector of 371
Institutional and government
47
Inputs
  • Funds adding, latest quarter35 · 40 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$265K · 53 pct, sector of 133
Risk and compliance
47
Inputs
  • Short interest, % of float+26.6% · 6 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+3.8% · 88 pct, sector of 511
4 not measured: Profitability, Growth, Insider conviction, US patents
  • Profitability needs 2 of 4 inputs, 1 present: average equity is zero or negative; capital employed is zero or negative; tax provision or pre-tax income not filed for the four quarters
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies